Scotblood 2017 by Gareth Neil Design

YOUR PARTNER FOR BLOOD BANKING, SEROLOGY & TISSUE BANKING PRODUCTS Our products are manufactured within our purpose built laboratories and Class A clean room to GMP standards.

Our products are ISO 9001 certified, and comply with the standards and recommendations set out by the British Blood Transfusion Society, the Council of SALINE PRODUCTS INCLUDING PBS REAGENT GRADE WATER

Europe and the Red Book (Guidelines for the Blood Transfusion Services of the United Kingdom).

RED CELL STORAGE SOLUTIONS

WHY SOURCE BIOSCIENCE?

SEROLOGY TESTING CONTROLS

- Products manufactured within our purpose built laboratory & Class A clean room

LECTIN PRODUCTS FETAL CELL DETECTION RANGE

- 30 years experience - Extensive portfolio of high-quality products

TISSUE BANKING REAGENTS

- Bespoke products available on request

INFECTION CONTROL RANGE

- Rapid dispatch times for standard products - Delivered where you want, when you want - Online shop to speed up your ordering process - Competitive prices with discounts on large volume orders & all volumes catered for

sourcebioscience.com

S E R V I C E S

P R O D U C T S

SCOTBLOOD 2017 ANNUAL CONFERENCE

INDEX 3 Index 5

Chaiman’s Welcome

Conference programme, info & accommodation

PLENARY SESSION I – RDI – Advanced Therapeutics

Engineering Minature Human Hearts Professor Ron Li, Univeristy of Hong Kong

Blood Sweat and Ears Dr Chris West, University of Edinburgh

The Potential of CAR T cells Dr David Gilham, Vice President, Research & Development, Celyad, Belgium

PLENARY SESSION II – Clinical Success

50 years of RhD therapy Prof Alan Cameron MD FRCOG, University of Glasgow

Ovarian tissue transplantation Prof Evelyn Telfer, University of Edinburgh

Harvey’s Gang Mr Malcolm Robinson, Western Sussex NHS

PLENARY SESSION III – Maintaining the Supply Chain

Major Incident Management - Paris and Nice Dr Pierre Tiberghien, French Blood Establishment

Implementation of HEV testing - Clinical & Practical Dr Angus Wells & Mr Alan Smith SNBTS

21 A Segmented Supply Chain Strategy for Blood Components Professor Christine Rutherford, Heriot-Watt University

PLENARY SESSION IV – Donor Services

Changing the Donor Selection Rules on Sexual Risk : Issues and Consideration Dr Moira Carter, SNBTS

IAIN COOK MEMORIAL LECTURE

From Dolly to Treatment of Human Disease Prof Sir Ian Wilmut

COPLAND LIFE-TIME ACHIEVEMENT AWARD

Dr Sam Rawlinson OBE >> 3

SCOTBLOOD 2017 ANNUAL CONFERENCE

INDEX 26

Commercial Exhibitors

Poster Index

73 Organisers 74 Acknowledgements 75 Certificate 77

Scotblood 2017 map

SCOTBLOOD 2017 ANNUAL CONFERENCE

CHAIRMAN’S WELCOME David Colligan Chairman, Scotblood 2017 Organising Committee Dear Delegate,

On a personal note, I would like to thank all the members of the Scotblood Organising Committee for their tireless effort in supporting and organising this event. I have seen at first hand the considerable effort that goes on behind the scenes to make this meeting run smoothly and I am very grateful to all of them. The organisation of the scientific programme, the Commercial Exhibition, the conference booklet and the operation of the conference requires dedication and hard work which is all given voluntarily by SNBTS staff. Our thanks must also go to the staff at the University of Stirling and the SNBTS and NSS Boards for their support of the Conference.

On behalf of the Organising Committee, it is a great pleasure to welcome you to the University of Stirling and Scotblood 2017. A new development for 2017 is the introduction of an online booklet with further information on our speakers, details of the posters and which also includes a CPD certificate. We hope you take advantage of this resource as we look to reduce our environmental impact. Scotblood has always been proud of our ability to attract internationally renowned speakers, presenting the important and emerging issues in transfusion and transplantation.

We would also like to thank the Companies whose patronage allows us to deliver this event. The long lasting relationships between the Conference and the Commercial Exhibitors are such that they continue to return and enjoy their attendance. I would like to stress that without these companies and their financial support this Conference would not be possible on this scale. Can I urge all of the delegates to make a concerted effort to meet and speak with the exhibitors, whether they are a regular, or one of our new exhibitors.

The 2017 programme includes a wide variety of speakers to discuss local and international developments. In the programme this year we will have a timely discussion on donor eligibility and how this can, and will, affect blood services. Additionally, with the emergence of Advanced Therapeutics within SNBTS, we have a number of notable speakers discussing some of the exciting emerging cell therapies that SNBTS will be involved in developing and delivering in the future.

Finally we would like to thank you, the delegates, for your support of Scotblood. This is your conference and we would be delighted to have your feedback, or if you would like to be involved at a local level then please ask one of our co-ordinators. It is your participation that makes it such a great annual event.

We are also delighted that Sir Ian Wilmut will be delivering the Iain Cook Memorial Lecture. Sir Ian is a World renowned scientist and speaker, and I am sure that his talk on the advancement of regenerative medicine from the beginning with “Dolly” will be both entertaining and informative.

I hope you all enjoy Scotblood 2017.

The Thursday evening social event has a Scottish inspired theme. I am sure that the food, hospitality and entertainment will be of the high standard that Scotblood is rightfully well renowned for.

David Colligan Chairman, Scotblood 2017 Organising Committee 5

SCOTBLOOD 2017 ANNUAL CONFERENCE

CONFERENCE PROGRAMME, INFO & ACCOMMODATION

SCOTBLOOD 2017 ANNUAL CONFERENCE

Thursday 8th June

All sessions in Logie Lecture Theatre unless otherwise indicated

08.30 – 09.30

Coffee, registration and setting up of posters

09.30 – 10.00

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mr Colin Sinclair, NSS

10.00 – 12.00

Plenary Session I – RDI – Advanced Therapeutics

Engineering Miniature Human Hearts . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Prof Ron Li University of Hong Kong Blood Sweat and Ears . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dr Christopher West University of Edinburgh

The Potential of CAR-T cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dr David Gilham, Celyad

12:00 – 14:00

Opening of Commercial Exhibition, Lunch, poster viewing

14:00 – 15:30

Plenary Session II - Clinical Success

50 years of RhD therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Prof Alan Cameron University of Glasgow Ovarian tissue transplantation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Prof Evelyn Telfer University of Edinburgh Harvey’s Gang . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mr Malcolm Robinson Western Sussex NHS 15:30 – 16:00

Coffee/tea, poster viewing and commercial exhibition

16:00 – 17:30

Plenary Session III – Maintaining the Supply Chain

Major Incident Management - Paris and Nice . . . . . . . . . . . . . . . . Dr Pierre Tiberghien EFS (French Blood Establishment) Implementation of HEV testing- Clinical & Practical . . . . . . . . . . . . . . . Dr Angus Wells & Mr Alan Smith, SNBTS A Segmented Supply Chain Strategy for Blood Components . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Prof Christine Rutherford Heriot-Watt University 18:30 –midnight

Reception, Scottish Themed Buffet Dinner and Disco

SCOTBLOOD 2017 ANNUAL CONFERENCE

Friday 9th June

All sessions in Logie Lecture Theatre unless otherwise indicated

08:30 – 09:30

Coffee and registration

9:30 – 11:00

Plenary Session IV – Donor Services

Donor Selection for Sexual Risk: Safety or Discrimination? Lets Talk about sex and Donor Selection? . . . . . . . . . . . . . . . . Dr Moira Carter, SNBTS

Campaigning for Change . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Mr Scott Cuthbertson Development Manager, Equalities Network 11:00 – 11:30

Coffee/tea, poster viewing, commercial exhibition

11:30 – 12:30

Iain Cook Memorial Lecture

From Dolly to Treatment of Human Disease . . . . . . . . . . . . . . . . . . . Prof Sir Ian Wilmut University of Edinburgh

12:30 – 12:45

Copland Lifetime Achievement Award . . . . . . . . . . . . . . . . . . . Dr Sam Rawlinson, SNBTS

12.45 – 14:00

Lunch, poster viewing and prize giving

14:00 – 16.00

Concurrent Sessions incorporating presentations from selected abstracts and MSc students

(I) Donor Services (II) Immunohaematology & Blood banking (III) Advanced Therapeutics / T&C

(I)

Donor Services

Donor Services and Transport Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . Moira Carter Introducing the Donor Portal . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Lynne Willdigg

Rolling Out Appointments Action Plan . . . . . . . . . . . . . . . . . . . . . . . Cara McGuigan and Debbie McNaughton Thinking through the reduction in Red Cell Demand . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Victoria Shirran and Andrew Reid

More Sex Talk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fionagh Thomson and Angus Wells

Open Forum . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Angus Wells, Moira Carter et al 8

SCOTBLOOD 2017 ANNUAL CONFERENCE

(II)

Immunohaematology & Blood Banking

Genotype vs Phenotype . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Martin Maley Reference Service Manager, Newcastle BTS Reference Lab Reporting in the 21st Century . . . . . . . . . . . . . . . . . . . . . . Mark Williams Head of Reference Services, NHSBT Emergency Medical Retrieval Services “Blood on Board” . . . . . . . . . . Dr Neil Hughes Consultant in Emergency Medicine

(III)

Advanced Therapeutics

Development of T cell therapies for BK and Hepatitis E viruses – . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Dr Stuart Imlach SNBTS Improving Dendritic Cell Therapy for Cancer Using a Novel Chemokine-Based Sorting Method . . . . . . . . . . . . . . Mr Paul Burgoyne University of Glasgow/SNBTS Developing a GMP Process for Isolation of Hepatic Progenitor Cells from Biliary Ducts . . . . . . . . . . . . . Mr Jonathon Sentance SNBTS Cell replacement therapies for Parkinson’s Disease . . . . . . . . . . . Dr Maurice Canham SNBTS

SCOTBLOOD 2017 ANNUAL CONFERENCE

Conference & Accomodation Online Conference Booklet

Social Event

For 2017 we are introducing an online booklet with further information on our speakers, details of the posters and a CPD certificate. Details to access the online booklet will be included in your delegate pack and will also be available at the registration desk.

The social evening for Thursday 8th June will have a buffet style menu (Scottish Themed). A cash bar will be open from 1830 onwards with food and complimentary drink being served from 1900 onwards. A disco in the Studio Bar will start at 2030 until Midnight.

Accommodation Meals Accommodation for Scotblood delegates will be in Willow Court or Stirling Court Hotel. Key cards will be issued for Willow Court from the Reception Desk at Willow Court. Rooms will be available from 1200 on the day of arrival and must be vacated and keys returned to the Reception Desk by 1000 on the day of departure. Delegates with accommodation at Stirling Court Hotel can check-in after 1400 and should check out by 1000 on day of departure.

Please note that delegates MUST wear their conference badges at all times to receive conference meals, including breakfast at Refresh at Willow Court.. Thursday 8th June Breakfast . . . . . . . . . . . . 0730 to 0845 Refresh, Willow Court Lunch (Bento) . . . . . . . 1200 to 1400 Andrew Miller Atrium Buffet/Drinks . . . . . . . . 1830 to 2045 Andrew Miller Atrium

To comply with the Smoking, Health and Social Care (Scotland) Act 2005, which came into force on 26th March 2006. SMOKING IS PROHIBITED THROUGHOUT ALL UNIVERSITY BUILDINGS, AROUND ENTRANCES TO BUILDINGS AND WITHIN INTERNAL COURTYARDS.

Friday 9thJune Breakfast . . . . . . . . . . . . 0730 to 0845 Refresh, Willow Court Lunch (Bento) . . . . . . . 1245 to 1400 Andrew Miller Atrium

Shops

Parking

Shops are available for a variety of goods within the Andrew Miller Building, adjacent to the Atrium. In addition, there is a Bank located within this building, with cash machines available here.

Parking is available at Willow Court for residential delegates. Day delegates can park in Cottrell Car Parks. Delegates are requested not to park in Queenâ&#x20AC;&#x2122;s Court.

Commercial Exhibition The Commercial Exhibition will be in the Andrew Miller Atrium from 1000 on Thursday 8th June and will be open until 1400 on Friday 9th June. 10

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster Session

Continuing Professional Development

Posters should be displayed in the Andrew Miller/Cottrell link bridge by 1000 on Thursday 8th June and should be removed by 1700 on Friday 9th June.

A tear-off CPD Attendance Certificate is included at the rear of this Conference Booklet. Tea & Coffee

Please note there will be a prize for the best poster submitted.

Tea and Coffee will be available as follows:-

Telephone

Thursday 8th June 0830 to 0930 & 1530 to 1600 beside the Commercial Exhibition in Andrew Miller Atrium.

Telephone facilities are available throughout the University Campus. Urgent telephone messages on Thursday/Friday 0900 to 1700 should be made to Commercial Services at the University on 01786 466000. Outwith these hours, contact the main University switchboard at 01786 473171.

Friday 9th June 0830 to 0930 & 1100 to 1130 beside the Commercial Exhibition in Andrew Miller Atrium.

Contact telephone numbers for the residences are:Willow Court – 01786 466952 Stirling Court Hotel – 01786 451666 Please note during sessions mobiles should be switched off or turned to silent. Wi-Fi Delegates can take advantage of the Wi-Fi at Stirling University Registration Registration will be open at the following times:Thursday 8th June – 0830 to 1600 Friday 9th June – 0830 to 1400 The Registration Desk will be manned throughout the Conference to provide further information as required. For easy identification the organising committee will be wearing Grey Scotblood t-shirts.

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSIONS

IAIN COOK MEMORIAL LECTURE & COPLAND LIFE-TIME ACHIEVEMENT AWARD

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSION I – RDI – Advanced Therapeutics Engineering Minature Human Hearts Professor Ron Li Univeristy of Hong Kong Professor Ronald Li was the Founding Director of the Stem Cell & Regenerative Medicine Consortium (SCRMC) and S Y and H Y Cheng Endowed Professor in Stem Cell Biology and Regenerative Medicine at HKU.

Professor Li’s other accolades include American Heart Association (AHA)’s Best Study of 2005 and Ground-breaking Study of the 2006, Young Investigator Award from the Heart Rhythm Society (2002), and the Career Development Award from the Cardiac Arrhythmias Research & Education Foundation (2001).

He is currently affiliated with the Li Dak-Sum Center for Regenerative Medicine at HKU, and the Ming-Wai Lau Center for Regenerative Medicine, Karolinska Institute, Sweden. Since 1901, Karolinska Institute has been selecting Nobel Laureates in Medicine & Physiology. Previously, Professor Li was on the faculty of the Section of Cardiovascular Cell & Tissue Engineering at Icahn School of Medicine at Mount Sinai in Manhattan, NY, and the University of California, Davis where he led the Human Embryonic Stem Cell Consortium.

Professor Li’s main interest is in cardiac tissue engineering, with over 130 publications. Professor Li has served as a panel member of a range of international funding bodies including the NIH, AHA, Association Francaise contre les Myopathies, United States-Israel Binational Science Foundation, Research Grant Council of HK, Stem Cell Consortium, A*STAR/Biopolis of Singapore, Wellcome Trust and MRC of the UK, etc.

Before he was recruited to CA in light of the state’s USD$3-billion stem cell initiative Proposition 71, Professor Li was Assistant Professor of Medicine at the Johns Hopkins University. During Prof. Li’s tenure at Johns Hopkins School of Medicine, he was a 2-time recipient of the Top Young Faculty Award (2002, 2004), the Top Prize for the Young Investigator Basic Research (2001) and Top Postdoctoral Fellow (2001).

Professor Li’s inventions have led to several start-ups in the U.S. and Hong Kong, with the latest one being Novoheart, which specializes in engineering human heart tissues and chambers for revolutionizing drug discovery and development as well as cell-based regenerative heart therapies.

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSION I â&#x20AC;&#x201C; RDI â&#x20AC;&#x201C; Advanced Therapeutics Blood Sweat and Ears Dr Chris West University of Edinburgh Plastic surgery is a discipline that is defined by the aim to restore form and function. This often requires complex reconstruction of damaged and diseased tissue with significant morbidity to patients. Tissue engineering offers the possibility of eliminating much of this morbidity be growing new tissues that can be transplanted into patients. Fundamental to any successful tissue engineering is identifying suitable cells and scaffolds.

A high through-put polymer microarray platform was used to identify synthetic polymers that can be used as substrates for tissue engnineering. A library of over 2000 polymers was screened and 5 distinct polymers that support the attachment of cells and the stable proliferation over extended periods of culture were identified. In addition, the ability of specific polymers to support the subsequent differentiation into mesodermal line ages was evaluated.

Using immunohistochemistry to establish a unique surface marker profile, this work identifies microvascular pericytes as an in-vivo source of mesenchymal stem cells. Using Fluorescence Activated Cell Sorting, protocols were developed to prospectively purify these cells from human adipose tissue in numbers sufficient for clinical use without the need for ex-vivo expansion.

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSION I – RDI – Advanced Therapeutics The Potential of CAR T cells Dr David Gilham Vice President, Research & Development, Celyad, Belgium Cancer therapy is undergoing a revolution. The immune system that protects us all from infection by bacteria and viruses is now providing new approaches that can challenge cancer. The concept of exploiting the immune system to treat cancer is not now – well over 100 years old in fact. However, only recently has this potential now begun to translate into clinical reality with patients worldwide now being treated with immune-related drugs including antibodies, cytokines and cells.

cancer cells expend a lot of time and effort avoiding recognition by T cells – hence many patient succumb to cancer even though T cells are present within the body that could potentially eradicate the tumor. One approach that is now delivering early success in the clinic is engineering the T cell to provide a specificity that allows the T cell to re- recognize tumor cells. This approach is the basis of the Chimeric Antigen Receptor or CAR. Hence, T cells genetically engineered to with a CAR can target tumor cells avoiding the mechanisms cancers have developed to avoid being killed by T cells. The approach is most advanced in leukaemia with spectacular early clinical results. Translating this approach to the broader setting of solld cancers is the major goal of workers in the field.

A key member of the immune system is the T cell. This cell type resides within the blood and plays an active role in seeking out damaged and infected cells which they can then either kill directly or produce soluble cytokine messengers that co-opt further elements of the immune system to deal with the identified danger. T cells can also potentially kill cancer cells. However,

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSION II – Clinical Success 50 years of RhD therapy Prof Alan Cameron MD FRCOG University of Glasgow Alan has been a Consultant Obstetrician in Glasgow for 25 years. He undertook his subspeciality training in Maternal Fetal Medicine in the University of Calgary, Alberta, Canada. After this he was appointed Lecturer in the Department of Obstetrics and Gynaecology in Glasgow.

He chaired the Scottish Committee of the RCOG from 2009-13. He is the RCOG representative on the National Screening Committee and is involved in various projects with the Fetal Anomaly Screening Programme. He was the local President when the European Board of Obstetrics and Gynaecology took place in Glasgow in 2014.

He has retained an active research profile and he was rewarded with an Honorary Professorship from the University of Glasgow in 2007. His main research interests are in prenatal diagnosis and fetal therapy. He was the Scottish Members representative on RCOG Council from 1996-2002 and was President of the British Maternal and Fetal Medicine Society from 2005-08.

From 2013 – 16 he was Vice President for Clinical Quality at the RCOG. He is the co-principal investigator of the flagship RCOG project ‘Each Baby Counts’ and is senior clinical adviser to the Lindsay Stewart Centre at the RCOG

As a former chair of the RCR/RCOG standing joint committee he helped develop the current RCOG Ultrasound training modules. In 2008 he was elected as the Scottish Fellows representative on RCOG Council and was re-elected in 2011.

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSION II â&#x20AC;&#x201C; Clinical Success Ovarian tissue transplantation Prof Evelyn Telfer University of Edinburgh Professor Evelyn Telfer holds a personal chair in Reproductive Biology at the University of Edinburgh. Evelyn was awarded her PhD in ovarian development from the University of Edinburgh in 1987 and now heads a research group in Ovarian Development. The groupâ&#x20AC;&#x2122;s interests cover all aspects of follicle and oocyte development in mammals with particular interest in developing in vitro models to support oocyte development from primordial stages in domestic species and human.

Her group is now focusing on the function of female germ line stem cells isolated from adult ovaries. Evelyn has a wide network of basic science and clinical collaborations with groups in the U.K., Europe and the U.S.A. Her research is funded mainly by MRC.

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSION II – Clinical Success Harvey’s Gang Mr Malcolm Robinson Western Sussex NHS I am looking forward to telling you a story about a boy, an inquisitive 7 year old lad, Harvey Buster Baldwin, who inspired me and reinvigorated the team to provide a better service to patients.

Harvey’s Gang was winner of the Kate Granger 2015 Team award for Compassionate Care; I was presented with the award by my heroine, the late Dr Kate Granger MBE. We also won the 2016 Chief Scientific Officer’s award for Patient and Public Participation I really hope that you’ll come and listen to our story at Scotblood 2017 and find out where this journey has taken us, where we are now, and where we are going. Then allow us to help you expand this to your Trust or country.

Harvey’s Gang has helped us understand that what we do every day DOES matter. It has motivated us to do our best at work every day and gives us job satisfaction, which in today’s cash-strapped NHS is unique. (So we are told 5 times in our CQC report: Outstanding NHS Trust).

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSION III – Maintaining the Supply Chain Major Incident Management - Paris and Nice Dr Pierre Tiberghien French Blood Establishment Pierre Tiberghien is Deputy CEO in charge of Medicine, Research and Innovation at the French transfusion public service (Etablissement Français du Sang - EFS) and Professor of Immunology at the Besançon Medical School, University of Franche-Comté. He studied Medicine and Human Biology and is certified in Internal Medicine, Clinical Hematology and Medical Oncology. Besides, he continued his scientific career obtaining a PhD in Immunology. As a post-doctoral student and visiting scientist, he spent two years at the National Cancer Institute in

Frederick, Maryland, USA. Subsequently, he headed a research laboratory in transplantation immunology and cell engineering. He is the Director of a “HostGraft Interactions” Master degree – a cooperation of 4 French universities since 2008. Pierre Tiberghien is vice-president of the European Blood Alliance since June 2017. As EFS deputy CEO in charge of Medicine, he is involved in all decisions regarding transfusion medicine and safety in France.

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSION III â&#x20AC;&#x201C; Maintaining the Supply Chain Implementation of HEV testing- Clinical & Practical Dr Angus Wells & Mr Alan Smith SNBTS The symptoms of Hepatitis E virus (HEV) infection can vary from no apparent symptoms to liver failure. HEV can be transmitted by blood transfusion and the virus can cause persistent infection and chronic inflammation of the liver in susceptible transfusion recipients.

Our presentation will review the implementation of universal HEV testing and the subsequent steps taken to manage untested stocks of blood components and tissues. Up to one in 1700 donors test positive for HEV and we will review our experience of positive donors to date.

SNBTS started testing selected blood donations for HEV in 2016. Later that year, the UK Advisory Committee for the Safety of Blood Tissues and Organs (SaBTO) undertook a further review of the indications of HEV negative blood components. This recommended that all immunocompromised patients receive HEV negative components. Therefore it became more cost effective to test all donations as this makes simplified stock management for SNBTS and hospital blood banks.

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSION III â&#x20AC;&#x201C; Maintaining the Supply Chain A Segmented Supply Chain Strategy for Blood Components Professor Christine Rutherford Heriot-Watt University In 2014 the SNBTS and Heriot-Watt University began a three year Knowledge Transfer Partnership (KTP) to design an adaptive, future proof supply chain and inventory strategy for the SNBTS.

In this research component criticality from the customerâ&#x20AC;&#x2122;s perspective (hospital and patient) is identified as a key criterion to be considered in the selection of supply chain strategy. We combine criticality with shelf life and the demand (transfusion) characteristics of each component and propose a taxonomy for supply chain selection for SNBTS adoption.

This presentation will focus on the research completed in Phase One of the KTP project: Supply Chain Strategy Design. When dealing with a range of diverse products it is essential that we categorise products using relevant criteria so that we can identify the best supply chain strategy for each category. Segmentation criteria commonly used by industry, such as product value and profit contribution, do not apply in healthcare where the life-saving potential of products must take priority.

21 21

SCOTBLOOD 2017 ANNUAL CONFERENCE

PLENARY SESSION IV - Donor Services Changing the Donor Selection Rules on Sexual Risk : Issues and Consideration Dr Moira Carter SNBTS In 2011, SaBTO endorsed the recommendation made by the Donor Selection Subcommittee on Donor Selection to reduce the deferral period for Men who have had sex with Men (MSM ) to 12 months rather than the permanent exclusion in place at that time. In addition, requested that the impact and effectiveness of this change be monitored and reviewed and that the UK Blood Services assessed compliance with Donor Selection Criteria.

While the relaxation of the permanent exclusion to a time-based deferral was welcomed by stakeholders it was recognised that this did not enable monogamous sexually active MSM’s and other affected donors to donate. In the intervening period. There has been increasing pressure from those affected by this rule for the UK blood services to implement ‘individual’ risk assessment that would enable more MSM’s to donate.

During 2016, SaBTO commissioned a subcommittee to undertake a further review of Donor Selection in potential donor’s risk of acquiring blood borne infections. The remit of the included the review the of evidence base for donor selection and exclusion in the UK in relation to the following behaviours, sexual contact, recreational drug use and piercing of the skin. The workgroup was tasked with making recommendations to SaBTO on the most appropriate ways to maintain a safe and sufficient blood supply and assess whether current deferrals are appropriate acknowledging that patient safety is paramount.

This session will consider the review mechanism and explore the issues surrounding this complex area and the implications for blood services.

SCOTBLOOD 2017 ANNUAL CONFERENCE

IAIN COOK MEMORIAL LECTURE From Dolly to Treatment of Human Disease Prof Sir Ian Wilmut

Sir Ian Wilmut is a world-renowned embryologist and specialist in regenerative medicine. He is best known as the man who led the team that in 1996 first cloned a mammal, a Finn Dorset lamb named “Dolly”. Dolly was the first ever clone derived from an adult cell. The research resulting in Dolly’s birth stemmed from efforts to genetically engineer sheep and cows in order that their milk would contain human proteins with medicinal properties, such as human antibodies.

The new Centre covers the full spectrum of research – from basic mechanisms of stem cell biology, to clinical trials with stem cells and their derivatives. The aim of his own research is to be able to produce human cells for use in research and in future for treatment of diseases, such as motor Neuron Disease. In his talk he will describe the way in which the cloning research has provided revolutionary new opportunities in regenerative medicine.

More recently he was the founding Director of the Centre for Regenerative Medicine in the University of Edinburgh. The Mission of this rapidly expanding Centre is to develop new treatments for human disease through innovative research with stem cells.

SCOTBLOOD 2017 ANNUAL CONFERENCE

COPLAND LIFE-TIME ACHIEVEMENT AWARD Dr Sam Rawlinson OBE Born: 5 July, 1958, in Colchester, Essex. Died: 13 March, 2016, in Abernethy, Perthshire, aged 57.

Obituary Sam Rawlinson stood out from the crowd in so many arenas: war zones; the medical field; youth work and his more personal relationships. But those to whom he made the greatest difference, through an extraordinary life cut prematurely short, may not even have known his name. People like the injured soldier who received more than 70 pints of blood thanks to his work helping to design and deliver a blood transfusion service on the battlefield that has now been adopted across the UK

schools in Sussex and was discovered to be dyslexic after achieving almost top marks in Maths but a terrible score in English. Initially he had ambitions to become either a vet or an archaeologist and although he was interviewed for admission to Cambridge University he wasn’t keen on the institution so opted instead to go to St Andrews. He went up in 1976 and there he met his future wife, Dr Beena Raschkes, becoming engaged after just one date and marrying as students in 1981. By that time he had graduated with a BSc and was at Manchester University medical school studying for his MBChB. He qualified in 1982 and took junior medical and surgical jobs at Manchester’s Withington Hospital and then Park Hospital, Davyhulme, Trafford, the birthplace of the NHS .

Though he insisted its success was down to outstanding team work from experts at home, in NATO, the RAF and in healthcare in Afghanistan and Iraq, he was a fiercely determined force behind the initiative, a man never to shirk commitment or duty, and his contribution was recognised with awards of both Healthcare Reservist of the Year and an OBE. In his spare time, such as it was, he and his wife volunteered as helpers and assessors for the Duke of Edinburgh awards and had just been about to take a group of youngsters kayaking in Canada when he was diagnosed with a malignant brain tumour. Having survived two Gulf Wars, this was one adversity he could not overcome although, as in everything he took on, he tackled it in his own way – even receiving the ward escape routes to abscond for a “pipe break”, hotly pursued by half a dozen nurses.

Although his interest in blood had originated during his time at St Andrews, it developed further when he had duties as a laboratory biomedical scientist at Manchester Royal Infirmary. That experience gave him a breadth and depth of knowledge of blood and testing as well as an understanding of the work and functioning of laboratories. He followed that with a post as registrar in the bone marrow transplant unit and haematology department of Glasgow Royal Infirmary which he joined in 1987. Meanwhile he was also a member of the Territorial Army, having signed up as a student to counteract his concern that he was missing out on some of the more exciting outdoor pursuits the world had to offer. He spent a total of 22 years in the Royal Army Medical Corps and commanded both Dundee-based 225 General Support Medical Regiment and 205 Scottish Field Hospital.

Peter Samuel Marshall Rawlinson – “Colonel Sam” to his military colleagues – was born in Colchester, the son of Dr Peter Rawlinson and his wife Diana, a nurse, and lived above his father’s GP surgery. He was educated at Holmwood House Prep and Felsted 24

SCOTBLOOD 2017 ANNUAL CONFERENCE

But it was during his time in Glasgow that he served in Operation Granby, the first Gulf War, in 1991. The experience of that conflict continued to resonate with him down the years and changed the career route he wished to pursue. He had applied for a haematology post at Leeds Royal Infirmary but told the hospital he had decided he should really be looking for a transfusion position instead. As a result they employed him as a transfusion specialist and he spent two years there as a senior registrar.

work I do in my military role is benefiting my day job back in Scotland. We’ve substantially upgraded the clinical practice for patients with severe trauma, based on military experience out in the field.” The following year he was made an OBE. After more than two decades’ service with the TA, which he could not have completed without the support of his wife, he felt the couple could make a difference together and chose the Duke of Edinburgh Award scheme. They took youngsters, including those from a special needs group, on expeditions to the hills and were thrilled by the transformation they could bring about. They sea kayaked around the Summer Isles in preparation for their Canadian trip but last June he was diagnosed with cancer. In his final nine months he astounded friends, family and health professionals with his upbeat attitude and courageous approach to his illness. He planned his own funeral, which included music from the soundtracks of the films Good Morning Vietnam and The Great Escape, plus Monty Python’s Always Look On The Bright Side Of Life, and, appropriately, I Vow To Thee My Country. He is survived by his wife Beena, and their sons Benno, an endurance racer and adventurer, and Fraser, a rugby player and Royal Marine.

He then took up a post as a civilian haematology consultant at the Army Blood Supply Depot in Aldershot, Hampshire, before moving to Scotland in 1996 as consultant for the Scottish National Blood Transfusion Service (SNBTS). He became clinical director of the East of Scotland Blood Transfusion service, based at Dundee’s Ninewells Hospital, in 1999 and latterly was the clinical lead for SNBTS Clinical Transfusion Laboratories based in Edinburgh, Glasgow, Dundee, Aberdeen and Inverness. He also went on to serve in the second Gulf War, Operation Telic, which began in 2003. In addition Rawlinson was Defence Consultant Advisor (DCA) for Transfusion Medicine and UK Blood Transfusion Advisor to NATO for five years, from 2005-09, and visited both Iraq and Afghanistan a number of times as DCA. He helped to design and deliver a transfusion service that provided transfusion support to patients injured in Afghanistan and Iraq, for both pre-hospital transfusion support and massive transfusion. Originally used in a military setting, these developments have been adopted UK-wide.

Sam also told the BBC Scotland news website that he could not have done it without the support of his colleagues, who take up the slack while he is away, and also his wife Beena Raschkes, who is a GP in Bridge of Earn. He said: “My wife has been fantastic, there’s no way that you could do TA for 20 years without your wife supporting you, it just doesn’t happen. “Obviously she’s had to put up with the tours and me disappearing and going a little bit funny or nervous before I go out, because I always do. “You abandon your wife and your children and she just has to pick up the pieces and crack on.”

In 2008 he was named Healthcare Reservist of the Year at the Military and Civilian Health Partnership Awards in London and praised by Scotland’s then public health minister Shona Robison for his inspirational work and commitment to healthcare which she described as “second to none”. At the time he said: “Without a doubt the 25

SCOTBLOOD 2017 ANNUAL CONFERENCE

COMMERCIAL EXHIBITORS

COMMERCIAL EXHIBITOR

A HEALTHIER COMMUNITY THRIVES WITH A HEALTHIER BLOOD AND PLASMA SUPPLY

At Abbott, we understand the vital role each blood and plasma service has on the health system. That is why we have been committed to the safety of the world’s blood and plasma supply for over 40 years. Moving forward, we are partnering with our customers to help them achieve measurably better healthcare performance and innovate the products and services they provide to the healthcare community. Discover our Transfusion Medicine personalized solutions on www.transfusion.abbott

COMMERCIAL EXHIBITOR

Better Blood Transfusion Team Scottish National Blood Transfusion Service 21 Ellenâ&#x20AC;&#x2122;s Glen Road Edinburgh EH17 7QT

The Better Blood Transfusion (BBT) team, since its inception in 2003, continues to make blood transfusion safer, more effective and efficient.

The BBT team delivers improvements through a wide range of projects and initiatives and achievements over the last 13 years have seen changes to the way blood is used and how clinicians practice.

Operating throughout Scotland, with representation in every health board and a central programme team based in Edinburgh, BBT remains committed to the original guiding principles of the appropriate use of the donorâ&#x20AC;&#x2122;s gift and safety of transfusion for the patient.

COMMERCIAL EXHIBITOR

GRIFOLS IS ONCE AGAIN PROUD TO SUPPORT THE 2017 SCOTBLOOD ANNUAL CONFERENCE Please visit us and we will be delighted to present our range of products and services for the modern Blood Transfusion Laboratory. Our unique 8 well DG Gel Cards offer a cost effective high quality flexible alternative to the traditional Gel Card format. We are also pleased to present our full range of automated systems for blood bank laboratories, including The Erytra high throughput analyser and our new benchtop Erytra Eflexis analyser, which enables us to provide a flexible solution for every laboratory, large or small. Also our Procleix NAT solutions for donor testing laboratories. We look forward to meeting you.

Grifols UK Byron House Cambridge Business Park Cambridge CB4 0WZ UK Telephone 0845 241 3090 FAX 0845 241 3314 diagnostics.uk@grifols.com

COMMERCIAL EXHIBITOR

To learn more about Haemonetics, visit our booth No. 7 Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. Haemonetics Ltd. Business Innovation Centre Harry Weston Road Coventry CV3 2TX United Kingdom T: 0808.234.4817 F: 0808.234.4845 info.uk@haemonetics.com For a list of worldwide office locations and contact information, visit www.haemonetics.com/officelocations ÂŠ 2016 Haemonetics Corporation. Haemonetics is a registered trademarks of Haemonetics Corporation in the USA, other countries, or both. 06.2016 Germany.

COMMERCIAL EXHIBITOR

Shouldnâ&#x20AC;&#x2122;t you be using professionals for your annual maintenance and calibration?

Visit the Labcold team at Scotblood 2017 to find out more

All blood bank refrigerators, plasma freezers, platelet incubators and agitators are specialist professional pieces of equipment. Shouldnâ&#x20AC;&#x2122;t you use professional specialists to maintain them? Labcold are specialist medical device manufacturers of blood product storage equipment. Our Technical Service team are UKAS trained, professional, medical refrigeration specialists. We are also a UKAS accredited calibration laboratory No. 8898.

( 01256 705 580 www.labcold.com 35

8898

COMMERCIAL EXHIBITOR

OO BL

RO DP

CESS

ING

BLO OD

SA F

Y ET

1977-2017

MACOPHARMA

BLOOD COLLEC TI O N

BY YOUR

ING

CORD BLOOD

SIDE FOR

T PHO

TOPH

ERESIS

CU CELL

R LTU

> TRANSFUSION > BIOTHERAPY

www.macopharma.com MACOPHARMA UK - 8th Floor - Regal House 70 London Road Twickenham Middlesex TW1 3QS UNITED KINGDOM - T. + 44 (0) 20 8892 2922

COMMERCIAL EXHIBITOR

STEWARDSHIP KNOWLEDGE INNOVATION EXCELLENCE The Micronclean SKIEs initiative - at the very heart of everything we do at Micronclean

THINK YOU KNOW MICRONCLEAN? LOOK CLOSER! WE ARE RENOWNED FOR OUR RENTAL SERVICE, BUT WE OFFER SO MUCH MORE . TAKE A LOOK ONLINE.

www.micronclean.co.uk T: 01754 767377 E: enquiries@micronclean.co.uk W: www.micronclean.com Consumables website

COMMERCIAL EXHIBITOR

Your trusted partner on the path to immunotherapy Learn how you can simplify every step of your immunology workflow:

Tissue dissociation

Cell isolation

Cell activation and expansion

Miltenyi Biotec Ltd. Almac House, Church Lane | Bisley, Surrey GU24 9DR | United Kingdom | Phone +44 1483 799 800 Fax +44 1483 799 811 | macs@miltenyibiotec.co.uk | www.miltenyibiotec.com Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Flow cytometry

Clinical applications

miltenyibiotec.com

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. MACS is a registered trademark of Miltenyi Biotec GmbH. Copyright ÂŠ 2016 Miltenyi Biotec GmbH. All rights reserved.

COMMERCIAL EXHIBITOR

A Fully Integrated & Advanced Software Solution Blood Bank

Transfusion Services

Tissue & Cells

Powerful Blood Establishment Computer System

The Best Software for Patient Transfusion Activities. In combination with ePROGESA, organizations can achieve vein to vein traceability

Ultimate Tissue & Cell Software Solution from Collection until Transplantation

ePROGESA

eTRACE LINE

T.C.S.

www.mak-system.com 39

COMMERCIAL EXHIBITOR

NHS National Services Scotland NSS Healthy Working Lives 1 South Gyle Crescent Edinburgh EH12 9EB 0131 275 7441

The NSS Healthy Working Lives Team is delighted to be able to support Scotblood 2017

The services are Training, Information and resources on Occupational Health, Health and Safety, and Workplace Health and Wellbeing.

Our team consists of 12 members and our aim is to support staff by providing ways to help them maintain and improve their health and wellbeing, by providing a wide range of services that support a Healthy and Safe Working Culture and Environment.

To find out more about our team please visit our NSS Healthy Working Lives Exhibition Stand.

COMMERCIAL EXHIBITOR

Quality: itâ&#x20AC;&#x2122;s in our blood

Biomedical -40ÂşC Plasma Freezers. The ideal freezing environment for the preservation of fresh frozen plasma. MBR Blood Bank Refrigerators are designed to conform to the strictest blood storage regulations, with assured stable and reliable temperature controls that utilise original technology from Panasonic. Panasonic Biomedical Sales Europe BV. 9 The Office Village, North Road Loughborough. Leicestershire. LE11 1QJ Tel: 01509 265265 Web: www.panasonic-healthcare.com/uk/biomedical Email: biomedical.uk@eu.panasonic-healthcare.com

COMMERCIAL EXHIBITOR

Shape the future With the cobas® 6800/8800 systems The future of donor screening is in your hands With transformative performance, automation and ﬂexibility, the cobas® 6800/8800 systems are redeﬁning molecular testing for donor screening. Experience unprecedented throughput, faster time to results, mixed batching and a consolidated menu—all with just 3 human touchpoints per run. Look into the future of molecular testing at www.cobas68008800.com

Not available in all markets.

COBAS and LIFE NEEDS ANSWERS are trademarks of Roche. © 2017 Roche Diagnostics Limited. All rights reserved Roche Diagnostics Limited Charles Avenue, Burgess Hill, West Sussex, RH15 9RY UNITED KINGDOM Company Registration Number: 571546 www.molecular.roche.com

www.cobas68008800.com

COMMERCIAL EXHIBITOR

Serious Hazards of Transfusion (SHOT) SHOT Office, Manchester Blood Centre, Plymouth Grove, Manchester, M13 9LL T: 0161 423 4208 E: SHOT@nhsbt.nhs.uk www.shotuk.org

Serious Hazards of Transfusion (SHOT) is the UKâ&#x20AC;&#x2122;s independent, professionally-led haemovigilance scheme. It started in 1996 and was one of the first such schemes in the world. SHOT collects and analyses anonymised information on adverse events and reactions in blood transfusion from all healthcare organisations that are involved in the transfusion of blood and blood components in the UK. Where risks and problems are identified, SHOT produces recommendations in the Annual SHOT Report to improve patient safety. Haemovigilance is an ongoing exercise, so SHOT also monitors the effect of the implementation of its recommendations.

The Annual SHOT Symposium in held in July each year to launch the newly published Annual SHOT Report. The 2017 symposium to launch the report of cases submitted in the calendar year 2016 will be held on Wednesday 12 July at Rothamsted Centre for Research and Enterprise, Harpenden, Hertfordshire AL5 2JQ Further information on the forthcoming symposium is available on the SHOT website www.shotuk.org along with many educational resources produced by SHOT.

COMMERCIAL EXHIBITOR

YOUR PARTNER FOR BLOOD BANKING, SEROLOGY & TISSUE BANKING PRODUCTS Our products are manufactured within our purpose built laboratories and Class A clean room to GMP standards.

Europe and the Red Book (Guidelines for the Blood Transfusion Services of the United Kingdom).

RED CELL STORAGE SOLUTIONS

WHY SOURCE BIOSCIENCE?

SEROLOGY TESTING CONTROLS

- Products manufactured within our purpose built laboratory & Class A clean room

LECTIN PRODUCTS FETAL CELL DETECTION RANGE

- 30 years experience - Extensive portfolio of high-quality products

TISSUE BANKING REAGENTS

- Bespoke products available on request

INFECTION CONTROL RANGE

sourcebioscience.com

S E R V I C E S

P R O D U C T S

COMMERCIAL EXHIBITOR

Your STARLAB Account Manager is Lisa Valenti-Randell: 07720 079195 / lisa@starlab.co.uk

COMMERCIAL EXHIBITOR

TERUMO BCT EUROPE NV Ikaroslaan 41 1930 â&#x20AC;&#x201C; Zaventem, Belgium Tel: 01452 729292 Fax: 01452 729293 Email: CSUK@terumobct.com

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. www.terumobct.com

COMMERCIAL EXHIBITOR

At a time when the monitoring of blood and biological products has never been more necessary - the QTA Tracer from Tridentify gives you complete and continuous compliance - and peace of mind. With its real-time tracking, linked to blue-tooth connectivity to your in-house systems QTA lets you tell, at a glance, with a full online graphic audit trail - which blood bags and other products, can be safely used - or disposed of. QTA (in Trials elsewhere in Scandinavia and Europe) - is a proven system, and has saved Hospitals nearly 74% of blood that otherwise would have been routinely thrown away resulting in savings of thousands of Pounds. Whether from just across the room - or in transit at any time of its life - you can be sure, at any time, of the stability of the livings cells and organisms that you are monitoring, and whether this has been compromised in any way in its life journey for your patients. QTA is a unique Tracer, that fixes simply to whatever blood bag or product you wish to monitor. It can be reused after use. It is waterproof, and can support typical theatre cleaning processes - and used again. It includes an internal battery, that powers the Tracer internal chip. It is registered as a Medical Device, and uses its own artificial intelligence algorithm to store data and evaluate in real time the quality control of the biological product associated. A simple red or green LED on the Tracer - gives immediate at a glance information on the suitability of the product in question. With full mobile connectivity, QTA data can connect, anywhere, to your iPhone and iPad, giving you details Reports, wherever you choose, - or you can automatically store larger data over time, on a Cloud - to evaluate at a later date - thus avoiding any errors of double writing of product codes or measurements. QTA removes the risk of uncertainty, and gives you complete knowledge of the status of each product you wish to tag and trace, over all of its life, As we say, - let us take you from “hoping” to “knowing”.

Johan Snis, johan.snis@tridentify.se, +4670 511 1803 Tridentify AB, Enrisvägen 33b, 475 40 Hönö

COMMERCIAL EXHIBITOR

Packaging on the

Because large-scale, temperaturesensitive materials shouldn’t require large-scale shipping budgets, World Courier gives you Cocoon.

A breakthrough in passive thermal packaging, Cocoon maintains its temperature 25% longer yet weighs 30% less, reducing shipping costs while ensuring product quality. It’s the first of many next-level innovations to come from World Courier’s Climate Optimization and Research Engineering (CORE) Labs, and the only one backed by the most trusted global supply chain and specialty logistics company in the world. When demand for your time- and temperaturesensitive transports increase, count on World Courier to innovate.

Learn more at worldcourier.com.

COMMERCIAL EXHIBITOR

SCOTBLOOD 2017 ANNUAL CONFERENCE

POSTERS

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster Index Poster No

1st Author

Title

Affiliation

PASS Chloe

Advanced Therapeutics, SNBTS

McLEAN Colin

BIENEK Carol

LARRALDE Osmany

GMP Translation, Validation and Clinical Trial Authorisation of a Macrophage Cell Therapy Product for Liver Cirrhosis. Comparing the effect of cryopreservation on overnight held buffy-coat derived platelet pools suspended in either plasma or SSP+. A Phase I/II Clinical Trial of Allogeneic ex vivo expanded Corneal Epithelial Stem Cells i Patients with Severe Ocular Surface disorder arising from Limbal Stem Cell Deficiency. Peptides that mimic epitopes of HEV capsid

TELFER Kwanruthai

SNBTS

McCONNELL Sylvia

Review of anti-D prophylaxis in Tayside – identifying reasons for sensitisation despite maternal participation in the routine anti-D prophylaxis programme. Clinical Interaction to Ensure optimum management of platelet refractoriness

HARRISON Elaine

Continuity Improving Safety

BBT, SNBTS

MALLOCH Katherine Just in Time

QEUH. Greater Glasgow & Clyde Health Board. BBT SNBTS

URQUHART Leo

Delays in Administration of Anti-D Immunoglobulin.

QEUH. Greater Glasgow & Clyde Health Board. BBT SNBTS

COYLE Sophie

Use of wastage of fresh frozen plasma units in the Queen Elizabeth University Hospital.

QEUH, Glasgow, BBT SNBTS

ESENKAN Marie

Flowing in the right direction.

Queen Elizabeth University Hospital Glasgow

FORRESTER M

Pre Term Infant transfusion support: adult or cord blood donation?

Univ. Aberdeen, SNBTS RDI, NHS Grampian Neonatal Unit.

BHANDARI Radhika

Aberdeen SNBTS

BHANDARI Radhika

McINALLY Carol-Anne

Assessment of half volume Pak Lx protocol for the detection of human platelet antigen (HPA) specific antibody. Investigation of prozone effect in solid phase immunoassay (SPI) Pak Lx and monoclonal antibody immobilisation of platelet antigens (MAIPA) utilised for the detection of human platelet antigen (HPA) specific antibody. HEV: The first year.

McGOVERN Margaret

Bags of Confidence

NHS Ayrshire & Arran

THOMSON Calum

NHS Scotland

SEBTS, SNBTS & RDI SNBTS SCRM, SNBTS

Microbiology RDI, SNBTS

SNBTS

Aberdeen SNBTS

MRU, SNBTS

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 1 GMP Translation, Validation and Clinical Trial Authorisation of a Macrophage Cell Therapy Product for Liver Cirrhosis. ChloĂŤ Pass (1), Neil McGowan (1), Anne Atkinson (1), Alasdair Fraser (1), Emily Hargreaves (1), Laura Bailey (1), Stuart Doig (1), Donna Mitchell (1), Benjamin Dwyer (2), Coral MacRury (2), Francesca Moroni (2), Alison Glover (1), Jacqueline Barry (3), Michaela Sharpe (3) , Natalie Mount (3), Marc Turner (1), John Campbell (1,2), Stuart Forbes (2) 1: Advanced Therapeutics, SNBTS. 2: University of Edinburgh 3: Cell and Gene Therapy Catapult.

Liver cirrhosis is the result of chronic liver injury due to many causes including obesity, alcohol, metabolic, viral and autoimmune disease. This leads to a lack of functioning liver cells and pathologically increased scarring. In the UK, mortality from cirrhosis has tripled over the last 30 years with liver disease now the 5th most common cause of death. Whilst liver transplant can be curative, it requires lifelong immunosuppression. There are no clinical methods for stimulating liver regeneration in the cirrhotic liver to improve liver function. Macrophages are a heterogeneous population of cells with diverse roles within the liver including phagocytosis, maintaining immune tolerance and both fibrosis promotion and resolution. Preclinical data from our group has demonstrated that autologous macrophage therapy can improve liver function by reducing fibrosis and stimulating regeneration.

The primary objectives of the MATCH study are to demonstrate safety and efficacy of MDMs in patients with advanced liver cirrhosis. Participants receive one infusion of MDMs seven days post-leukapheresis. Phase I is a dose escalation study to establish the maximum tolerated dose (MTD) of autologous MDMs. Phase II is a randomised/controlled efficacy study. Patients will receive standard medical care or three doses of autologous MDMs at monthly intervals. The primary outcome measure is the demonstration of improved liver function three months post-infusion (Phase II). Secondary outcome measures include improved markers of liver fibrosis, improved disease related quality of life, reduced liver related clinical events and improved transplant free survival. Phase I (dose escalation) has now been completed without any serious events, with the final patient receiving dose 3 (â&#x2030;¤10^9 macrophages) on the 10th April 2017. Phase II will commence as soon as possible following review of the Phase I data.

The process of culturing autologous monocyte-derived macrophages (MDMs) was translated to GMP grade (n=11) and validated (n=3) to establish a manufacturing process for the production of an autologous MDM cell therapy product for use in a Medical Research Council-funded first-in-man clinical trial, entitled Macrophage Therapy for Liver Cirrhosis (MATCH 0.1, EudraCT 2015-00096315). The trial design, process and preclinical data were discussed with the MHRA, with Clinical Trial Authorisation in January 2016. 54

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 2 Comparing the Effect of Cryopreservation on Overnight Held Buffy-coat Derived Platelet Pools Suspended in either Plasma or SSP+ Colin McLean (1), Loraine McMillan (2), Jillian Stephen (2) Alex Morrison (2) Juraj Petrik(2) 1: SNBTS, South East BTS, Edinburgh, SNBTS, 2: National Science Laboratory, Edinburgh, UK Background Cryopreservation of platelets has predominantly been performed with apheresis platelets in 100% plasma. Given the move away from apheresis components in the UK and the use of platelet additive solution, combined with the introduction of overnight hold of whole blood donations prior to processing. It would be useful to evaluate freezing of platelets produced via the buffy-coat route of production.

deterioration of platelet parameters post thaw, regardless of media stored and re-suspended into. We observed increases in cell surface phosphatidylserine expression as measured by Annexin V (3.1±1.0 – 56.4±13.9% for plasma and 3.6±1.3 – 50.1±1.5% for SSP+), this combined with increases in microparticle concentrations is suggestive of platelet activation, however measurements of CD62p (p selectin) showed no significant changes over storage. While we also observed CD42b (GP1bα) levels to decrease in plasma (53.1±10.1 – 23.5±6.2 MFI) but did not note any significant change when stored in SSP+ (51.1±4.9 – 53.7±16.0 MFI). Thromboelastography (TEG) analysis indicated the platelets were more hypercoagulable as seen with reduced coagulation R times (plasma pre 13.0 ± 1.4 mins v plasma post 6.0 ± 0.4 mins) (SSP+ pre 9.7 ± 1.6mins v SSP+ post 5.2 ± 1.1mins). The speed of this coagulation was quicker in plasma thawed platelets than SSP+ (plasma post 0.9 ± 0.2 v SSP+ post 1.1 ± 0.2) however, significance was only observed for the thawed plasma samples p 0.001, while SSP+ samples showed no significant change throughout storage. Overall platelets were still functional as observed with the TEG clotting times and clot strengths and supported by data from the impact R coagulation assay were adhesion and aggregation was still observed post cryopreservation.

Aim To compare buffy-coat produced platelet units suspended in either plasma or SSP+. Cryopreserved and then resuspended into either 100% fresh plasma or 100% fresh SSP+ solution. Methods Day 2 platelet concentrates were prepared from overnight held whole blood units, either suspended in 100% plasma or 70% SSP+ and 30% plasma. To these units 6% v/v DMSO was added, an empty satellite bag was attached and units centrifuged. Excess plasma/ SSP+ was expressed off leaving approximately 20mL in the original storage bag. These platelet pellets were then re-suspended, wrapped in protective packaging and stored at -80°C. On thawing, platelets were either re-constituted in fresh plasma or 100% SSP+. Sample analysis was assessed pre cryopreservation, post thaw and post 4 hours. Measurements of functionality, metabolism, morphology, activation and quality were all assessed. All measurements are reported as means ± standard deviation and any differences P<0.05 were considered significant. N=10

Summary/conclusions Overnight held buffycoat platelets prepared in additive (70:30) and then re-suspended post thaw into 100% additive solution, can be effectively frozen and retain function comparable to those stored in 100% plasma. Because of safety and standardisation issues with plasma, we suggest that thawing platelets into an additive such as SSP+ may be beneficial, for cryopreserved platelet units.

Results Following cryopreservation, we observed a platelet recovery of 87% for units stored in plasma and 78% in SSP+. Over the course of the study pH remained stable with all values falling comfortably within the UK “red book” guidelines (≥6.4). However we did note a 55

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 3 A phase i/ii clinical trial of allogeneic ex vivo expanded corneal epithelial stem cells in patients with severe ocular surface disorder arising from limbal stem cell deficiency Carol Bienek(1), Anne Atkinson (1), Neil McGowan (1), Alison Glover(1), Emily Hargreaves (1), Alasdair Fraser(1), John Campbell (1), John Drain (1), Jacqueline Barry(1&6), Bruce Cuthbertson (1), Catherine Rooney(1), Jane Pelly(1), Louis Nerukar(2), Margaret Macdonald (3), Ashish Agrawal (3), Kanna Ramaesh (4), Sanjay Mantry(4), Sajjad Ahmad (5), Stephen Kaye (5), Bal Dhillon (3), & Marc Turner(1) 1: Scottish National Blood Transfusion Service (SNBTS) Advanced Therapeutics, Edinburgh; 2: University of Glasgow; 3: Princess Alexandra Eye Pavilion, NHS Lothian, Edinburgh; 4: Tennent Institute of Ophthalmology, Greater Glasgow and Clyde, Glasgow; 5: St Paulâ&#x20AC;&#x2122;s Eye Unit, Royal Liverpool University Hospital, Liverpool; 6: Cell and Gene Therapy Catapult, London. Limbal stem cell deficiency (LSCD) is an irreversible disease resulting from the loss or dysfunction of corneal epithelial stem cells leading to a thickened, irregular, unstable epithelium, often with secondary neovascularisation.

received cataract operations during the trial which would have improved their score. 4/5 patients in the control arm also showed improved visual acuity scores, though to a lesser degree, (1 cataract op.). The increase in score did not reach statistical significance in either arm due to the small data set and large variance.

LSCD affecting a single eye may be treated with autologous corneal epithelial stem cells from the healthy eye, whilst patients with bilateral disease require an alternative starting material.

All patients showed improved combined ocular surface scores (OSS) at the conclusion of the trial. In the IMP group, OSS was significantly improved by 6 months and remained so throughout the trial. A significant improvement was not observed in the control group and the difference between groups was statistically significant.

We have carried out a randomised controlled Phase I/II clinical trial of deceased-donor derived allogeneic corneal epithelial stem cells on amniotic membrane with amniotic membrane alone used in the control arm.

This Phase I/II study demonstrates that it is feasible to generate corneal epithelial stem cells from deceased allogeneic donors using a xeno-free GMP culture process for multi-centre clinical administration. The IMP proved safe and there was improvement in visual acuity and ocular surface score in both the IMP and control arms of the study, and superior improvement in ocular surface score in the IMP arm of the study.

All patients received topical autologous serum eye drops and systemic immunosuppression. The primary endpoint was improvement in visual acuity, secondary endpoints included ocular surface score and quality of life. 16 patients were recruited to the study, 13 were evaluable, and of these 5 had Aniridia, 6 chemical burns and 2 autoimmune conditions. 8 patients received the investigational medicinal product (IMP) and 5 the control.

This early data is promising, but needs evaluated in a properly powered Phase III clinical trial focused on a less heterogeneous patient population and more precision in the care pathway.

No serious adverse events were ascribed to the IMP itself. 5/8 patients treated with the IMP finished the trial with an improved visual acuity score, however 2 patients 56

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 4 Peptides that mimic epitopes of HEV capsid Osmany Larralde & Juraj Petrik Microbiology RDI, SNBTS, NHS, Edinburgh Hepatitis E is an emerging zoonotic infection of increasing public health threat for the UK, especially for immunosuppressed individuals. A human recombinant vaccine has been licensed only in China and is not clear whether it protects against hepatitis E virus (HEV) genotype 3, the most prevalent in Europe. The aim of this study was to use phage display technology as a tool to identify peptides that mimic epitopes of HEV capsid (mimotopes). We identified putative linear and conformational mimotopes using sera from Scottish blood donors that have the immunological imprint of past HEV infection. Four mimotopes did not have homology with the primary sequence of HEV ORF2 capsid but competed effectively with a

commercial HEV antigen for binding to antiHEV reference serum. When the reactivity profile of each mimotope was compared with Wantai HEV-IgG ELISA, the most sensitive HEV immunoassay, mimotopes showed 95.2â&#x20AC;&#x201C;100% sensitivity while the specificity ranged from 81.5 to 95.8%. PepSurf algorithm was used to map affinity-selected peptides onto the ORF2 crystal structure of HEV genotype 3, which predicted that these four mimototopes are clustered in the P domain of ORF2 capsid, near conformational epitopes of anti-HEV neutralising monoclonal antibodies. These HEV mimotopes may have potential applications in the design of structural vaccines and the development of new diagnostic tests.

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 5 Review of anti-D prophylaxis in Tayside – identifying reasons for sensitisation despite maternal participation in the routine anti-D prophylaxis programme. Kwanruthai Telfer Scottish National Blood Transfusion Service Background Anti-D Ig prophylaxis has had a significant impact in modern obstetrics. It has significantly reduced the rate of anti-D sensitisation since it was first introduced from 16% to around 1%. Despite unsensitised Rh D negative pregnant women receiving antenatal and postnatal prophylaxis, there is continuing sensitisation. An evaluation of the anti-D prophylaxis programme in Tayside may identify possible reasons for continuing anti-D sensitisation.

Results This study identified non-compliance with guidelines. Anti-D sensitisation rate in Rh D negative pregnant women in Tayside is 0.55%, which is below the national average of 1% but does not meet the 0.35% national target. Conclusion This study has highlighted that, for some women, there have been episodes of non compliancenon-compliance to Anti-D Ig prophylaxis guidelines and failure to correctly administer anti-D Ig prophylaxis following potentially sensitising events. However, sensitisation continues to occur despite strict adherence to guidelines due to “silent” sensitising events or other unknown causes.

Methods A retrospective review of the anti-D Ig prophylaxis programme in Tayside between January 2010 and December 2015 will identify the outcome of anti-D Ig errors and improve understanding of the reasons for continuing anti-D isoimmunisation. The following objectives were set to assess this: 1. To Identify the incidence of Rh D sensitisation in pregnant women in Tayside 2. To compare local data for Rh D sensitisation with published data 3. To determine whether sensitised women had received anti-D Ig prophylaxis during pregnancy in Tayside in accordance with national evidence based guidelines. 4. To identify the potential reasons for failure of routine anti-D Ig prophylaxis in Tayside 5. To suggest strategies to reduce the risk of Rh D sensitisation in future.

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 6 Clinical Interaction to Ensure optimum Management of Platelet Refractoriness Sylvia McConnell Scottish National Blood Transfusion Service Thrombocytopenia is a complication that can occur in haematological malignancy, marrow failure or after treatments such as chemotherapy. Random ABO RhD compatible platelets are administered either as prophylaxis to minimise the risk of bleeding or as therapy (1). It is critical that the effectiveness of platelet transfusion is monitored to recognise signs of poor response. Platelet refractoriness is defined as the failure of a patient’s platelet count to increment above 10 x 10>9/L at between one and 24 hours following transfusion of two or more units of fresh ABO RhD compatible pooled platelets (2). The identification of platelet refractoriness due to HLA specific antibodies is important as patients with immune refractoriness can be supported with HLA compatible apheresis donor platelets which result in an improvement in platelet counts in 60-70% of cases (3). The main measure of HLA matched platelet transfusion efficacy is the monitoring of patients’ platelet counts pre and post-transfusion.

platelet transfusion counts were obtained as a baseline. Platelet counts were reaudited following the introduction of NATF1004 between 01/12/16 and 31/03/17 to see if its introduction increased the number of platelet counts received. The number of pre and post platelet counts received nationally between 01/05/16 and 31/08/16 was <1%. Following the issue of NATF1004, the number of counts received rose to 44.35%, comparable to NHSBT who have a return of approximately 34% (4). Therefore the introduction of NATF1004 has improved the feedback given to H&I labs on platelet increments which enables better management of immunological refractory cases by allowing selection of the most effective donations for patients who require HLA selected platelets. References: 1. Wandt H, Shaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012;380:1309-1316. 2. Brown C. Guidelines for the management of platelet transfusion refractoriness. Information document 2011; INF139/1.1. 3. West A. User Guide for Histocompatibility and Immunogenetics Diagnostics Service 2015; INF136/3 4. NHSBT Transfusion Matters. Platelets - Safe and appropriate use. 9th Edition 2012.

To bring SNBTS in line with current practice in NHSBT, a new ‘Selected Platelets Follow-Up’ national form (NATF1004) was introduced on the 28th of November 2016, to collect platelet increment data from patients with immunological platelet refractoriness. Introduction of this new form required the interaction of multiple departments across SNBTS including H&I, P&T, Donor Services as well as external clinical contacts. Data was collated over a four-month period from 01/05/16 to 31/08/16 to assess the proportion of units issued to platelet refractory cases. Pre and post

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 7 Continuity Improving Safety Elaine Harrison, Margaret McGarvey, Alison Hanlon, Annie McEneny Better Blood Transfusion, Scottish National Blood Transfusion Service; Queen Elizabeth University Hospital, Greater Glasgow & Clyde Health Board Background Following incident investigation and trending, it became apparent that clinical staff reported challenges accessing the electronic requesting system during the haemorrhage situation.

Result This simple but effective process does not change the primary method of blood component requests which would always be via the electronic system; it is used as a support for the primary system. It allows for continuity of requests during a high-pressure and critical situation. Staff can be reassured, if they cannot log onto the electronic system for whatever reason, blood components can always be requested in a safe and effective manner. Initial feedback has been extremely positive as there is continuity across the campus in access to back-up paperwork if required.

Aim To ensure staff have access to a back-up paper based process to allow request of products during a haemorrhage or critical situation when electronic systems are unavailable for whatever reason. Method A simple â&#x20AC;&#x2DC;grab-bagâ&#x20AC;&#x2122; of all paperwork required to request blood components and have them delivered was developed. Firstly, a paper copy of the electronic request form had to be developed by Laboratory staff; this form mirrored all the fields in the electronic request form. This grab-bag contained paper copies of the request and collection form. Both of the major haemorrhage flow charts available for use in Queen Elizabeth University Hospital campus, one for paediatrics one for adults, fronted the grab-bag to draw attention to the contents. We requested via clinical huddles, that all grab-bags were retained within the resuscitation trolley in each ward and department to allow for continuity. The medical laboratory assistants delivered the grab-bags across the campus.

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 8 Just in Time Katherine Malloch (1), Lorraine Hamill (1), Margaret McGarvey(2), Elaine Harrison (2) 1: QEUH, NHSGGC, 2: Transfusion Practitioners, BBT, SNBTS Background Adult theatre services in Queen Elizabeth University Hospital (QEUH) became operational on May 1st 2015. By the 3rd of June, staff and services from the Western Infirmary, the Victoria Infirmary, the Southern General Hospital and some services and staff from Gartnavel General Hospital had amalgamated. There are now 22 theatres, including 2 Trauma and 2 CEPOD on the campus with approximately 300 perioperative staff. The model of blood delivery planned for the new campus included the purchase of a Haemobank satellite fridge which stores up to 80 units of blood.

Results Sufficient numbers of Perioperative staff were trained on the use of the fridge and issued with barcodes in time for opening in May 2015. The majority of Perioperative staff are now trained which allows full use of electronic and remote issue. Over 24,000 procedures have been carried out in Theatre since opening with rapid access to blood at the point of care. Summary/Conclusions Excellent communication and team working between the Laboratory and Theatre staff was critical to a successful outcome. A training programme has been set up for trainers in theatres to carry out revalidation sessions. Blood Bank staff will continue to train new members of staff as part of the induction programme.

Aims To provide rapid access to blood at the point of care. To ensure that theatre staff were trained to access the fridge whilst complying with MHRA regulations. Maintaining full theatre services on all existing sites until the move to the new campus was complete.

Acknowledgements Annie McEneny, MLA Supervisor, Blood Bank, QEUH, Marianne Murphy, MLA, Blood Bank, QEUH, All Blood Bank Staff from QEUH, All Perioperative Staff from QEUH.

Methods To install and validate fridge: to be fully functioning by the 1st of May 2015. Communication between the departments and key users provided invaluable information to focus on providing a service to multiple speciality Theatres. A training package was developed by the Laboratory staff and Theatre Education Co-ordinators. The delivery of the training relied on all staff being flexible in order to ensure that there would be no interruption to full patient services within the new hospital. The training was incorporated into the induction tours and occasional training sessions during nightshifts, weekends and public holidays.

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 9 Delays in Administration of Anti-D Immunoglobulin Leo Urquhart, Manimaalini Kunasegaran, Annie McEneny, Judith Roberts, Elaine Harrison. Queen Elizabeth University Hospital, Greater Glasgow & Clyde Health Board. Better Blood Transfusion Scottish National Blood Transfusion Service Background There is increased pressure to discharge women 6 hours post-delivery. One potential delay is waiting for administration of anti-D.

Conclusion The greatest improvement could be the time between anti-D being available and the request for issue. When anti-D is required on the day of request, laboratory staff call the clinical area to inform them of availability; how this information is subsequently shared in the ward requires further attention. Obstacles may be staff workload and movement of patients before anti-D is issued.

Aims Timeline the process of anti-D requests, from taking blood samples until administration to identify any areas of potential improvement. Methods A prospective audit over a two-week period gathered data on timings of blood samples taken, processed, anti-D issued and administered. This information was obtained from the laboratory and clinical IT systems and case records. 34 patients received anti-D during the audit period. Samples were taken from labour, post & antenatal wards, maternity assessment unit and day wards. Issues of anti-D to the routine prophylactic clinic were excluded.

Due to these factors the following recommendations can be made: - when the clinical area receive a call from the laboratory there needs to be continuity on how this information is shared accurately and timely - investigate the understanding and perceptions of all staff involved and provide information to highlight the potential for improving patient care.

Results Average delays for each step were as follows: • Sample collection until arrival of sample in the laboratory was 5hr 35m • Sample arriving in the laboratory until availability of anti-D was 2h 57m • Anti-D being available and a request for issue was 10hr 19m. This step represented the largest delay for 53% of women. • Clinical request for anti-D to time of issue was 2h 31min • Time of issue until administration to patient was 2h 16m

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 10 Use and Wastage of Fresh Frozen Plasma Units in The Queen Elizabeth University Hospital Sophie Coyle, Kieran McGivern, Elaine Harrison. The Queen Elizabeth University Hospital, Glasgow, BBT SNBTS Introduction The Queen Elizabeth University Hospital (QEUH) receives monthly data on FFP units requested and wasted due to time expiry or discard. This showed that over a seven-month period 20% of FFP units booked in were wasted.

Discussion 50% of patients in the Emergency Department for whom FFP was requested but wasted were trauma patients. In emergencies FFP may be ordered pre-emptively and discussions with Haematology not occur. Of note was a discrepancy in numbers of wasted units from national data compared to local data. This was found to represent units found damaged at thawing (4% n=49). Systematic review of RCTs has not demonstrated definitive indications for FFP use and studies conducted are of insufficient methodological quality. Without robust guidance, unnecessary requests will continue to be made. This data will be presented to the Hospital Transfusion Committee for dissemination to clinical areas to allow for sharing and assessment of best practice.

Aim To evaluate FFP requests and review units ordered but wasted, whilst identifying; • Requesting department • Patient condition • Reason for request • Other relevant information e.g. discussion with Haematology Method Between 01/04/16 and 30/10/16, issued units of FFP at the QEUH and the Royal Hospital for Children (RHC) were identified from the laboratory Telepath system and analysed by interrogation of patient records.

Conclusion Unclear FFP indications resulting in wastage is an on-going clinical issue. Clear, consistent, and easily available guidelines are required.

Results 448 requests for FFP were made in the QEUH and RHC totalling 1294 units. 253 were unused - a 20% wastage rate. 232 units were requested in the RHC. 45 were wasted. 1056 units were requested in the QEUH. 192 of these were wasted. • 40 units wasted by Obstetrics and Gynaecology • 52 of 192 requested units wasted by the Adult Emergency Department

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 11 Flowing in the right direction Marie Esenkan, Marie Arbuckle, Amanda Bothwell, Elaine Harrison. Queen Elizabeth University Hospital Glasgow; Better Blood Transfusion Scottish National Blood Transfusion Service Background Ensuring the patientsâ&#x20AC;&#x2122; journey through any episode of transfusion is a complex and multi-faceted event. Following analysis of the sample, the laboratory staff have new information which can impact on clinical decision making. The British Committee for Standard in Haematology; Guidelines for the specification, implementation and management of information technology systems in hospital transfusion laboratories (2014) continually recommend the use of standard comments when generating reports between the laboratory and the clinical area.

Results Agreement has been reached on the comments to be added to a patients Telepath record, furnishing clinical areas with information on sample retention, sample validity pre or post surgery date, storage of samples and if the patient is suitable for remote or electronic issue. This information has been recorded in a simple flow chart, directing staff to transcribe the correct comment. Conclusion This rewarding piece of work ensures uniformity of comments and is compliant with the relevant standards. Importantly there will be consistency and accuracy in information sharing, a vital part of the transfusion process. Ultimately transfusion safety has been enhanced.

Aims Within the Queen Elizabeth University Hospital Blood Transfusion Laboratory, there were multiple coded comments for the transfusion laboratory, with 27 comments directly relating to pregnant ladies. With the merge of three hospitals, variations in practice were expected. It was also recognised that not all staff were using all of the appropriate comments, with the risk that clinical staff did not have all the information they required to plan the patientsâ&#x20AC;&#x2122; journey.

Acknowledgements All Laboratory staff working in the Queen Elizabeth University Hospital

Method A review of the minimum comments required for individual situations was carried out. This included comments that could be added for pregnant patients, pre-operative patients with a negative antibody screen including previously transfused patients within the last three months. Relevant comments were categorised and collated relating to the individual scenario faced.

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 12 Pre-term infant transfusion support: adult or cord blood donation? M Forrester(1), S Armstrong-Fisher(1,2), S Mohamed Cassim (3), M Vickers (1,2) 1: Univ. of Aberdeen â&#x20AC;&#x201C; Immunity, Infection & Inflammation 2: SNBTS RDI - Clinical Transfusion 3: Neonatal Unit Aberdeen Maternity Hospital, NHS Grampian Background The second most common cause of death in premature babies is necrotising enterocolitis (NEC), caused by inflammation and ischaemic death of the gut. Several risk factors are implicated in the development of NEC, one of which is receiving a blood transfusion. However, a mechanism has not been established. Recent evidence suggests that new-born (cord) red blood cells (cRBC) can suppress potentially damaging immune responses to bacteria colonising the gut. If so, blood transfusions currently from adult donors might dilute these preventative properties, and facilitate damaging inflammatory responses against gut bacteria, predisposing to subsequent NEC.

Study design Residual routine blood samples (EDTA / Heparin; 50-500ul) were obtained from pre-term babies (delivery at 27-38 weeks gestation) in the NHS Grampian Neonatal Unit, after informed parental consent (Ethics: 14/NE/1209). Sequential samples were obtained until the infants were discharged. Methods Neonatal / cord / adult blood samples (n= 17, 21 & 23 respectively), were separated by density centrifugation over Lymphoprep into mononuclear (buffy) cell layer (MNC) and red cells (RBC). After washing, MNC and RBC populations were immunofluorescently labelled with PE mouse antihuman CD71/PE Cy7, mouse antihuman CD235a and analysed on a MACSQuantÂŽVYB flow cytometer.

We have previously assessed healthy umbilical cord blood (38-40 weeks delivery) and from healthy adults to investigate the antiinflammatory properties of newborn cRBC, with respect to proinflammatory and antiinflammatory cytokine production by immune cells in response to pathogenic gut bacteria (Listeria monocytogenes & Escherichia coli ). Simulated in vitro transfusions with either adult RBC or cord RBC were also conducted to determine if adult RBC affected new-born blood cells in a way that might predispose to NEC.

Results The proportion of CD71+ cells was significantly greater (p<0.0001) in both RBC and MNC populations from neonates (term cord and pre-term infants, RBC 2.19% and MNC 27.83%) compared to adults (RBC 0.272% and MNC 0.274%). If the immunosuppressive activity of these CD71+CD235a cells were confirmed, then transfusion with adult RBC lacking these cells might be reducing the efficacy of the innate progenitor RBC population through dilution and increasing the risk of uncontrolled inflammatory responses in the gut.

Aim: We wished to identify in neonatal cord blood samples the early red cell population (CD71+/ CD235+) purportedly responsible for immunosuppression, and to establish a time course for their development with respect to gestational age and compared to adult blood donors.

Conclusion Transfusion using umbilical cord progenitor RBC, rather than adult RBC donations, might offer advantages to pre-term infants to lessen their risk of post-transfusion NEC. 65

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 13 Assessment of half volume Pak Lx protocol for the detection of Human Platelet Antigen (HPA) specific antibody Radhika Bhandari, Dr Richard Battle SNBTS-Aberdeen Background Antibodies produced against Human Platelet Antigens (HPAs) are implicated in clinical conditions such as Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), Platelet Refractoriness (PTR) and PostTransfusion Purpura (PTP). Diagnosis and management of these conditions requires the detection and identification of HPAspecific antibody. The assays used for the identification of HPA antibodies includes; GTI Pak, Platelet Immunofluorescence Test (PIFT), Monoclonal Antibody Immobilisation of Platelet Antigens (MAIPA) and Pak Lx Assay. Each of these assay has relative advantages and disadvantages. The Pak Lx is a sensitive, specific and easy to perform test which has a fast turnaround with high throughput. However, the assay is costly (£1180/16 tests) when used as recommended by the manufacturer. This study assesses the performance of Pak Lx assay in detecting HPA- specific antibodies using half the volume of reagents (reduced reagent protocol) than stated by the manufacturer (full volume protocol) to obtain cost efficiency for platelet laboratories.

minimum potency (05/106). The reference reagents anti-HPA-1a (03/152), anti-HPA-3a (03/190) and anti-HPA-5b (99/666) from National Institute for Biological Reference Standards and Control (NIBSC) were titrated and analysed using the full volume and the reduced volume protocol in parallel. 3 patient samples (patient 1-Negative, patient 2- anti-HPA-1a, patient 3 -anti-HPA-5b), 2 EQA samples ( S1-anti-HPA-1a + anti-HPA-5b, S3-anti-HPA-1a) and a mixed positive control (pooled reference reagents 05/106, 03/190 and 99/666) were tested in parallel using both protocols. Analysis was performed using Luminex Xponent 3.1 and MATCHIT! Platelet antibody software to obtain MFI values and ratios for each reactive bead within the kit. The MFI values (580 datapoints) and the ratios (504 datapoints) from the full volume protocol were compared with the reduced volume protocol employing Spearman’s Rho correlation (rs), scatter plot and correlation coefficient (R2). Results No significant differences were noted in MFI values (p=0.722) and ratios ( p=0.195) for anti-HPA-1a titration(reference reagent 03/152) applying the criteria MFI >=700 and ratio >=1 for positivity. A strong correlation (rs>0.980, R2>0.97) was observed between full reagent and reduced reagent protocol. There were significant (p<0.05) differences in MFI values of anti-HPA-3a(03/190), antiHPA-5b (99/666) and patient and EQA samples between the full and reduced volume protocol. However differences in ratios between the two protocol were not significant (p>0.05) except for anti-HPA3a (03/190) where a significant (p=0.009) difference was noted. Both MFI values and >>

Method Patient and reference standard samples were analysed in parallel using manufacturer’s recommended volume (full volume protocol) and after reducing the reagents (reduced volume protocol). The manufacturer’s recommended volume 40ul beads, 10ul sera and 50ul Phycoerythrin (PE) conjugated goat anti-human IgG (PE-IgG) was reduced to 20ul beads, 5ul sera 25ul PE-IgG. PE-IgG saturation point for reduced reagent protocol was determined by titration of PE-IgG at 1:10, 1:60, 1:100 and 1:100 with anti-HPA-1a 66

SCOTBLOOD 2017 ANNUAL CONFERENCE

ratios between the two protocols were strongly correlated (rs>0.79 and R2>0.84).

protocol. The ability of both protocols to detect anti-HPA-3a and anti-HPA-5a was noted to be less sensitive than other methods. The sensitivity of both protocols to detect anti-HPA-1a was strongly correlated, the most frequently occurring antibody in HPA- specific antibody related clinical conditions.

Conclusion This study showed that Pak Lx reduced volume protocol is suitable to detect HPA antibodies with similar sensitivity to the manufacturer recommended (full volume)

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 14 Investigation of prozone effect in Solid Phase Immunoassay (SPI) Pak Lx and Monoclonal Antibody Immobilisation of Platelet Antigens (MAIPA) utilised for the detection of Human Platelet Antigen (HPA) specific Antibody Radhika Bhandari, Dr Richard Battle SNBTS-Aberdeen Background Diagnosis and management of Fetal and Neonatal Alloimmune Thrombocytopenia and Platelet Refractoriness involves the detection and identification of Human Platelet Antigen (HPA)-specific antibody. Routine assays employed to detect these antibodies include Solid Phase Immunoassays (SPIs). The sensitivity and specificity of SPIs may be affected by the presence of excess antibodies in the serum which can cause steric hindrance, monovalent binding or complement fixation, these processes can inhibit the binding of a detector/reporter Immunoglobulin (Ig) resulting in a low reporter signal and false assignment of the sample as negative. This phenomenon known as ‘prozone’ or ‘high-dose hook effect’ has been widely reported in the Single Antigen Bead (SAB)SPI detection of Human Leucoyte Anitgen (HLA) antibodies, the effect is reportedly abrogated by various modifications such as addition of Na2EDTA. This study investigates the occurrence of the prozone effect in Pak Lx and MAIPA HPA antibody detection assays, and utilizes Na2EDTA treatment and dilution to unmask any complement or high dose antibody mediated prozone effect.

1:8 diluted sera to observe any significant increment in the MFI and ratios. Detection of additional antibody, as indicated by MFI and ratios, after treatment would indicate complement mediated prozone (Na2EDTA treated) or prozone due to high dose/other mechanisms (1:8 dilution). To assess the MAIPA; samples previously tested were treated with Na2EDTA and retested. The Optical Density (OD) values from 28 sera samples directed against HPA-1a 3b, 25 sera samples directed against HPA-1b 3a or HPA-1b-3ab, and 26 sera samples directed against HPA-5a and 5b or 5ab were compared with the OD values from the untreated sera. Results In the Pak-Lx assay significant (p<0.05) differences in the MFI values and ratios were observed in the Na2EDTA treated and 1:8 diluted sera. 42 ratios corresponding to 8 samples in Na2EDTA treated sera were higher than the untreated sera. Of the 42 ratios higher in Na2EDTA treated group the increment was not significant (rs=0.982 and R2=0.979). With the exception of 1 sample (anti-HPA-5b) which was assigned negative in Na2EDTA treated sera and positive in untreated sera. 3 ratios corresponding to 1 sample were higher in a 1:8 diluted sera for HPA-1a bead out of 31 samples tested. The difference did not alter the samples positivity.

Method To assess the PaK Lx; 31 sera samples (22 FNAIT / PTR cases, 3 External Quality Assurance (EQA), 2 pooled, 2 negative and 2 positive controls) were tested in neat, after Na2EDTA treatment and following 1:8 dilution. The MFI values and ratios obtained from the untreated sera were compared with the Na2EDTA treated and

105 OD values from Na2EDTA treated samples were analysed in the MAIPA assay of which 12 were slightly higher in >> 68

SCOTBLOOD 2017 ANNUAL CONFERENCE

Conclusion Our study was not able to support the occurrence of prozone effect in Pak Lx and MAIPA assay. The small cohort of samples used here may have influenced this finding as such further studies are required.

Na2EDTA treated. However the increment was not significant. The mean OD value in untreated sera was 1.22 and 0.579 in Na2EDTA treated. However the data points were correlated (R2=0.801) between untreated and Na2EDTA treated samples.

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 15 HEV: The first year Carol-Anne McInally NMRU, SNBTS In February 2016, Hepatitis E virus (HEV) Nucleic acid Amplification Testing (NAT) was implemented in SNBTS in order to provide HEV RNA negative blood components for vulnerable patient. From 8th February 2016 to 31st March 2017 65590 donations have been tested for HEV with 25 confirmed as positive. The prevalence of HEV viraemia in Scottish blood donors varied throughout the year, with an overall prevalence rate of 1 in 2623. Similar published prevalence data is observed in England and France where as in Ireland, Sweden and the United States the prevalence rates are lower.

SaBTO approved updated recommendations on HEV testing in November 2016 (Published 20th December 2016) which included increasing the at risk patient groups who should receive HEV negative components. For cost effectiveness and operational reasons SaBTO recommended switching to universal screening. The project to implement universal testing that will require testing numbers to increase from ~50 000 to ~180,000 donations a year included electronic systems updates, communications with customers/user, stock management of nonscreened long shelf-life products (FFP and Cryoprecipitate) as well as manually testing >500 in-stock tissue and cell samples.

Of the 25 confirmed HEV positives the majority were acute infections (only positive for HEV RNA), with only 24% (n = 22) positive for IgM and IgG antibodies in addition to HEV RNA. No samples were serologically positive for only IgM antibodies. Lookback investigations on previous donations within the previous 4 months are required on all positive donors. In all instances this previous donation has been HEV negative confirming the acute nature of these infections.

SNBTS introduced universal screening of all blood component donations on 1st Mar 2017, and all tissue donations on 24th Apr 2017.

Of the 25 confirmed HEV positive donors 19 were male and only 6 female. 14 of the 25 HEV cases were in the age band 46 to 55. Once an infection is confirmed Public Health teams are notified. In addition the donor care team notify the donor, providing clinical advice. The donor is deferred for 6 months but after that time is able to return and donate as normal.

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 16 Bags of Confidence Margaret McGovern, Karen Smith NHS Ayrshire & Arran Background The Blood Safety and Quality Regulations (BSQR) require all blood components and blood products to be stored and transported at the correct temperature to ensure their efficacy and safety. Across NHS Ayrshire and Arran, transportation of blood components is a complex issue with nine hospitals relying on transportation of components from Crosshouse and Ayr Hospitals. Processes and logistics for transportation of components in temperature controlled conditions are validated, well established and multifaceted and deal with non NHS Staff such as Caledonian MacBrayne staff for transport to Arran. Blood for patients is historically transported through individual hospitals, including through some public areas without additional packing, which has the potential for patient details and the product to be viewed by the public. The Data Protection Act 1998 is the primary piece of legislation in the UK that protects individuals with regard to the processing of their personal data. Specifically Confidentiality and information sharing; Data quality; Individualâ&#x20AC;&#x2122;s rights about how their data is used and Information security.

new component transportation bags were purchased and trialled. The Bags were colour coded to individual products: Blue for Platelets, Yellow for Plasma, Red for Emergency Group O Negatives. These seal able bags also have additional pictorial information on correct patient identification procedures. Results Empirical data shows that Data Protection and Patient Confidentiality during the transit of blood components and products within the hospitals in Ayrshire is greatly improved. Staff who collect and deliver blood say they like the bags, find them easy to use and feel more confident going through public areas en route to wards. Ward staff have found the bags beneficial as they like the high visibility element of the bags, and find this useful in a busy ward as they draw attention to the blood component. Ward staff also find the patient identification checks aide memoir very useful. Conclusion These have been so successful that Bags of Confidence are ordered for all Red Cell Transfusions and will be implemented throughout Ayrshire in the next few weeks.

Aims To increase patient confidentiality and comply with the Data Protection Act 1998. Method During scoping exercise into delivery boxes we discovered that Data Protection could be enhanced by the addition of component transportation bags. Three

SCOTBLOOD 2017 ANNUAL CONFERENCE

Poster No 17 Leadership Development in the Virtual Environment QUBE ©Pentacle Calum Thomson, Heather Daniels, Kathryn Dick, Jane Oldham, Pauline Stewart, Tina Watson, Suzanne Whyte NHS Scotland Leading The Future – Virtual Leadership Programme The Leading Better Care Virtual Leadership Training Course was hosted entirely online using the platform “QUBE”. QUBE, a virtual business school, is currently being used across NSS and NHS Scotland to develop staff in innovation, leadership and agile project management to help drive forward change at speed. QUBE completely removes associated costs and time lost to travel and the requirement for suitable venues, meeting the needs of a national workforce.

Process • Virtual workshops and tutorials • Performance Enhancement Tools (PETS) – innovative tools that promote thinking differently and collaborative team working • Group work and final change project Performance • An ongoing network of staff who can support each other in new ways • Increased confidence for leading change in a dynamic environment Conclusion The course and delivery method provides candidates and facilitators, using an international platform, an opportunity to relearn in an agile and dynamic manner. Performance Enhancement Tools utilised to deliver course projects are also now being used effectively by delegates to support change in their workplace. The course design and content lends itself to multidisciplinary working. Combining the significant reduction to time and costs with a dynamic and modern method of delivery ensures a confident future for the virtual learning experience in NHS Scotland.

The Purpose of the Programme • Develop staff leadership skills in delivering change building on previous programmes • Aid development of effective succession planning The Principles of the Programme • Built on the Nursing and Midwifery Council (NMC) Code Pillars and revalidation (Prioritise People, Practice Effectively, Preserve Safety, Promote Professionalism and Trust) • Programme delivery in the context of Everyone Matters 2020 Workforce Vision People • Staff who have previously completed the Leading Better Care Programme • Facilitators from NSS, Senior Practitioners, QUBE, and Organisational Development

SCOTBLOOD 2017 ANNUAL CONFERENCE

Organisers

Core Group

David Colligan . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Chairman Lisa Bell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Commercial Exhibition Isabel Ward . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Commercial Exhibition Neil McGowan . . . . . . . . . . . . . . . . . . . . . . . . Scientific Programme & Posters Shirley Gibson . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SNBTS South East Caroline Casey . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SNBTS South East Anne Thomson . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SNBTS West Sandie Young . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Posters

Local Co-Ordinators

Lesley MacDonald . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SNBTS East Suzanne Milliken . . . . . . . . . . . . . . . . . . . . . . . . . . . SNBTS West (Athenaeum) Anne Thomson & Anne Howieson . . . . . . . . . . . . . . . . . . . . . . . . SNBTS West Colin Robertson . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SNBTS South East, RIE Catrina Hendry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SNBTS BBT Shirley Gibson . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SNBTS South East Gareth Walker . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . SNBTS South East

Programme Committee Neil McGowan David Colligan Moira Carter Marc Turner Rachel Green Anne Thomson

SCOTBLOOD 2017 ANNUAL CONFERENCE

Acknowledgements

The contribution of Sandie Young & Isabel Ward in the compilation of the Abstracts and Kirstin Thomson in the maintenance of the Scotblood Conference website is gratefully acknowledged. Additionally, the Organising Committee is grateful for the continuing support of the SNBTS & NSS Boards and the Commercial Contributors, without whose sponsorship this Conference would not be possible. The Scotblood Organising Committee and delegates are grateful to all the Commercial Companies who have financially supported this yearâ&#x20AC;&#x2122;s Conference by their attendance at the Commercial Exhibition. In addition, we would also like to acknowledge the number of Companies/ Organisations who have supported the event by additional sponsorship

Abbott Diagnostics Delegate Badges and Lanyards

Commercial Operations University of Stirling Notepads and Pens

SNBTS Pens and T-Shirts

SHOT Pens

Ortho Clinical Diagnostics Notepads

SCOTBLOOD 2016

SCOTBLOOD 2017 ANNUAL CONFERENCE

SCOTBLOOD 2016 ANNUAL CONFERENCE ANNUAL CONFERENCE SCOTBLOOD 2016

ANNUAL CONFERENCE CERTIFICATE OF ATTENDANCE

CERTIFICATE OF ATTENDANCE _______________________________________ CERTIFICATE OF ATTENDANCE _______________________________________ Attended the meeting on 8-9th June 2017 _______________________________________ Attended the meeting on

SCOTBLOOD 2017

8-9th June 2017 Attended the meeting on At the University of Stirling

SCOTBLOOD 2017 8-9th June 2017

At the University of Stirling

SCOTBLOOD 2017

David Colligan Neil McGowan At the University of Stirling On behalf of the Scotblood 2017 Organising Committee David Colligan Neil McGowan IBMS have awarded 15 credits for the whole meeting On behalfhave of the Scotblood 2017 for Organising Committee RCPath awarded 8 credits the whole meeting David Colligan Neil McGowan IBMS have awarded 15 credits for the whole meeting On behalfhave of the Scotblood 2017 for Organising Committee RCPath awarded 8 credits the whole meeting IBMS have awarded 15 credits for the whole meeting The Royal College of Pathologistshave awarded 8 credits for the whole meeting RCPath The Royal College of Pathologists 75